Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer

Author： Gonen M.  

Publisher： Elsevier

ISSN： 0197-2456

Source： Controlled Clinical Trials, Vol.24, Iss.4, 2003-08, pp. : 355-363

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Panitumumab in the Treatment of Metastatic Colorectal Cancer: Profile Report

By Hoy Sheridan M.   Wagstaff Antona J.  

BioDrugs, Vol. 21, Iss. 2, 2007-01 ,pp. : 135-137

Adis International

Access to resources Recommend Favorite

Spotlight on Panitumumab in Metastatic Colorectal Cancer†

By Keating Gillian M.  

BioDrugs, Vol. 24, Iss. 4, 2010-08 ,pp. : 275-278

Adis International

Access to resources Recommend Favorite

Spotlight on Bevacizumab in Metastatic Colorectal Cancer

By McCormack Paul L.   Keam Susan J.  

BioDrugs, Vol. 22, Iss. 5, 2008-01 ,pp. : 339-341

Adis International

Access to resources Recommend Favorite

Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: Analysis of Multiple Methods

By Li Shaotang  

BioDrugs, Vol. 25, Iss. 1, 2011-02 ,pp. : 43-50

Adis International

Access to resources Recommend Favorite

Panitumumab: In Metastatic Colorectal Cancer with Wild-Type KRAS

By Weber Juliane   McCormack Paul L.  

BioDrugs, Vol. 22, Iss. 6, 2008-01 ,pp. : 403-411

Adis International

Access to resources Recommend Favorite